NP2

AXP000200.1 · Viral vector gene therapy

Platform
HSV-1 (ICP4- ICP27-)
Targets
PENK
Originator
University of Michigan (David Fink)
Sponsor
Diamyd Medical

Names

NameTypeSource
NP2 ambiguouspreferred name, codecurator, paper
NP2 enkephalinsynonympaper

Virus

Role
In vivo gene transfer
Family
Herpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Replication
non replicating
Modifications
ICP4 and ICP27 deleted; human PENK under CMV IE promoter in both ICP4 loci
Transgenes
PENK
Route
intradermal
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (3)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05317195Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy SmokersCompleted2022-03-152022-05-0731Nicotine; Smoking
NCT01291901NP2 Enkephalin For Treatment of Intractable Cancer PainCompletedPhase 22011-012012-0733Intractable Pain; Neoplasms
NCT00804076Gene Transfer for Cancer PainCompletedPhase 12008-022010-1110Cancer Pain

Recent changes

No changes recorded in its trials yet.

Notes

Replication-defective HSV-1 vector deleted for ICP4 and ICP27 (and lacking ICP22/ICP47 promoters) carrying human preproenkephalin (PENK) under a CMV IE promoter in both ICP4 loci; injected intradermally in the painful dermatome. Phase 1 dose escalation in 10 patients with intractable cancer pain, NCT00804076, sponsored by Diamyd Incorporated (Ann Neurol 2011, PMID 21796661). Later taken forward by Periphagen; that transfer was not verified here.

How to cite

NP2 (AXP000200.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000200.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.